CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, California 94080
August 23, 2023
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara
| Re: | CytomX Therapeutics, Inc. |
| Registration Statement on Form S-3 |
| Filed August 16, 2023 |
| Registration No. 333-274010 |
Dear Mr. McNamara:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, CytomX Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on August 25, 2023, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Mark V. Roeder of Latham & Watkins LLP, counsel to the Company, at (650) 463-3043, or in his absence, John C. Williams of Latham & Watkins LLP at (415) 395-8223, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Thank you for your assistance in this matter.
* * * *
| Sincerely, | ||
| CytomX Therapeutics, Inc. | ||
| By: |
/s/ Lloyd A. Rowland | |
| Lloyd A. Rowland | ||
| General Counsel | ||
| cc: | Sean A. McCarthy, CytomX Therapeutics, Inc. |
| Christopher W. Ogden, CytomX Therapeutics, Inc. |
| Mark V. Roeder, Latham & Watkins LLP |
| John C. Williams, Latham & Watkins LLP |